NCCAM Sponsoring First Glucosamine/Chondroitin Sulfate Multicenter Study
This article was originally published in The Tan Sheet
Executive Summary
NCCAM is sponsoring the first U.S. multicenter study investigating the "short-term (16 weeks) effectiveness of glucosamine and chondroitin sulfate in reducing pain and improving function in a large number of patients with osteoarthritis of the knee," the National Institutes of Health National Center for Complementary & Alternative Medicine announced.
You may also be interested in...
Glucosamine/Chondroitin Supplier Selection Delays NIH Study
Difficulty in choosing a U.S. company to supply glucosamine and chondroitin sulfate has delayed the start of the NIH-funded study on osteoarthritis.
Glucosamine/Chondroitin Supplier Selection Delays NIH Study
Difficulty in choosing a U.S. company to supply glucosamine and chondroitin sulfate has delayed the start of the NIH-funded study on osteoarthritis.
Glucosamine/Chondroitin Supplier Selection Delays NIH Study
Difficulty in choosing a U.S. company to supply glucosamine and chondroitin sulfate has delayed the start of the NIH-funded study on osteoarthritis.